Associação entre lúpus eritematoso e tabagismo Association between lupus erythematosus and smoking
Anais Brasileiros de Dermatologia, 2008 FUNDAMENTOS: O lúpus eritematoso é doença crônica, auto-imune, que reúne manifestações exclusivamente cutâneas ou multissistêmicas, caracterizada pela produção de auto-anticorpos contra vários constituintes celulares.
Júnia Maria Fernandes Araújo +4 more
doaj +1 more source
Cancer risk factors in systemic lupus erythematosus: multivariate regression analysis in 16,409 patients [PDF]
, 2014 Peer ...
Anca Askanase +41 more
core +1 more source
Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease
Arthritis &Rheumatology, EarlyView.Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman +2 more
wiley +1 more source
Indian Journal of RheumatologyLupus erythematosus is an autoimmune disease characterised by the formation of various autoantibodies, leading to the involvement of numerous organ systems like the nervous system, renal system, and cutaneous involvement.
Smriti Gupta, Muthu Sendhil Kumaran
doaj +1 more source
Dermatology Reports, 2022 Lupus panniculitis is included in the chronic cutaneous lupus erythematosus group. A 18-year-old female patient came with the complaint of lumps on her face.
Agnes Rosarina Prita Sari +3 more
doaj +1 more source
Multigene Next-Generation Sequencing Panel Identifies Pathogenic Variants in Patients with Unknown Subtype of Epidermolysis Bullosa: Subclassification with Prognostic Implications [PDF]
, 2017 Purpose: Epidermolysis bullosa (EB), the prototype of heritable blistering diseases, is caused by mutations in as many as 19 distinct genes. In this study, we evaluated the molecular basis of EB in 93 families, many of them of unknown subtype. Methods:
Abiri, Maryam +15 more
core +1 more source
Efficacy and Safety of Methotrexate in Articular and Cutaneous Manifestations of systemic Lupus Erythematosus [PDF]
, 2012 Aim: A prospective open-label study comparing the efficacy and safety of methotrexate (MTX) and chloroquine (CQ) in articular and cutaneous manifestations of systemic lupus erythematosus (SLE). Methods: Consecutive SLE patients were randomly assigned
Alam, Mohammad N. +5 more
core +13 more sources
A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus
Arthritis &Rheumatology, EarlyView.Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen +14 more
wiley +1 more source
Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database. [PDF]
, 2017 Racial differences exist in the severity of systemic sclerosis (SSc). To enhance our knowledge about SSc in African Americans, we established a comprehensive clinical database from the largest multicenter cohort of African American SSc patients assembled
Boin, Francesco +28 more
core +1 more source